Deficiency of the procoagulant cofactor factor VIII (FVIII) in hemophilia A is routinely treated by protein replacement therapy with plasma-derived or recombinant FVIII. Now, a humanized bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback